Published in Cancer Res on February 09, 2011
Biomarkers of response to Akt inhibitor MK-2206 in breast cancer. Clin Cancer Res (2012) 1.44
Sensitization of cancer cells through reduction of total Akt and downregulation of salinomycin-induced pAkt, pGSk3β, pTSC2, and p4EBP1 by cotreatment with MK-2206. Biomed Res Int (2014) 1.41
MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis. Mol Cancer Ther (2011) 1.33
Therapeutic targeting of autophagy in disease: biology and pharmacology. Pharmacol Rev (2013) 1.25
MicroRNAs in autophagy and their emerging roles in crosstalk with apoptosis. Autophagy (2012) 1.10
Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer. PLoS One (2012) 1.06
Exploiting the potential of autophagy in cisplatin therapy: A new strategy to overcome resistance. Oncotarget (2015) 0.99
Targeting autophagy to sensitive glioma to temozolomide treatment. J Exp Clin Cancer Res (2016) 0.93
Survival and death of endoplasmic-reticulum-stressed cells: Role of autophagy. World J Biol Chem (2011) 0.92
Targeting the Cellular Signaling: BRAF Inhibition and Beyond for the Treatment of Metastatic Malignant Melanoma. Dermatol Res Pract (2011) 0.91
Targeting autophagic pathways for cancer drug discovery. Chin J Cancer (2012) 0.91
Regulation of autophagy by miR-30d impacts sensitivity of anaplastic thyroid carcinoma to cisplatin. Biochem Pharmacol (2013) 0.91
Current State of Animal (Mouse) Modeling in Melanoma Research. Cancer Growth Metastasis (2015) 0.91
Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo. Drug Des Devel Ther (2014) 0.90
Inhibition of eEF-2 kinase sensitizes human glioma cells to TRAIL and down-regulates Bcl-xL expression. Biochem Biophys Res Commun (2011) 0.90
Integrated regulation of autophagy and apoptosis by EEF2K controls cellular fate and modulates the efficacy of curcumin and velcade against tumor cells. Autophagy (2012) 0.90
The Akt signaling pathway: an emerging therapeutic target in malignant melanoma. Cancer Biol Ther (2011) 0.89
The Akt inhibitor MK-2206 enhances the cytotoxicity of paclitaxel (Taxol) and cisplatin in ovarian cancer cells. Naunyn Schmiedebergs Arch Pharmacol (2014) 0.88
Silencing of EEF2K (eukaryotic elongation factor-2 kinase) reveals AMPK-ULK1-dependent autophagy in colon cancer cells. Autophagy (2014) 0.86
Celecoxib regulates apoptosis and autophagy via the PI3K/Akt signaling pathway in SGC-7901 gastric cancer cells. Int J Mol Med (2014) 0.85
FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells. Oncotarget (2016) 0.84
Inhibition of elongation factor-2 kinase augments the antitumor activity of Temozolomide against glioma. PLoS One (2013) 0.84
Eukaryotic elongation factor 2 kinase confers tolerance to stress conditions in cancer cells. Cell Stress Chaperones (2014) 0.81
eEF-2 kinase is a critical regulator of Warburg effect through controlling PP2A-A synthesis. Oncogene (2016) 0.81
eEF-2 kinase, another meddler in the "yin and yang" of Akt-mediated cell fate? Autophagy (2011) 0.80
MK-2206, an AKT inhibitor, promotes caspase-independent cell death and inhibits leiomyoma growth. Endocrinology (2013) 0.80
AKT inhibitor suppresses hyperthermia-induced Ndrg2 phosphorylation in gastric cancer cells. Braz J Med Biol Res (2013) 0.79
The combination of tephrosin with 2-deoxy-D-glucose enhances the cytotoxicity via accelerating ATP depletion and blunting autophagy in human cancer cells. Cancer Biol Ther (2011) 0.78
Increased autophagy and apoptosis contribute to muscle atrophy in a myotonic dystrophy type 1 Drosophila model. Dis Model Mech (2015) 0.78
Elongation factor 2 kinase promotes cell survival by inhibiting protein synthesis without inducing autophagy. Cell Signal (2016) 0.77
Crosstalk between autophagy and apoptosis in RAW 264.7 macrophages infected with ectromelia orthopoxvirus. Viral Immunol (2013) 0.77
Healthy CD4+ T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia. Oncotarget (2016) 0.76
Downregulation of Choline Kinase-Alpha Enhances Autophagy in Tamoxifen-Resistant Breast Cancer Cells. PLoS One (2015) 0.76
Everolimus enhances cellular cytotoxicity of lapatinib via the eukaryotic elongation factor-2 kinase pathway in nasopharyngeal carcinoma cells. Onco Targets Ther (2016) 0.75
Akt/mTOR mediated induction of bystander effect signaling in a nucleus independent manner in irradiated human lung adenocarcinoma epithelial cells. Oncotarget (2017) 0.75
Endogenous transmembrane protein UT2 inhibits pSTAT3 and suppresses hematological malignancy. J Clin Invest (2016) 0.75
Curcuminoid EF24 enhances the anti-tumour activity of Akt inhibitor MK-2206 through ROS-mediated endoplasmic reticulum stress and mitochondrial dysfunction in gastric cancer. Br J Pharmacol (2017) 0.75
The allosteric AKT inhibitor MK2206 shows a synergistic interaction with chemotherapy and radiotherapy in glioblastoma spheroid cultures. BMC Cancer (2017) 0.75
Inhibition of eEF-2 kinase sensitizes human nasopharyngeal carcinoma cells to lapatinib-induced apoptosis through the Src and Erk pathways. BMC Cancer (2016) 0.75
Phospholipid scramblase 1 as a critical node at the crossroad between autophagy and apoptosis in mantle cell lymphoma. Oncotarget (2016) 0.75
Targeting translation initiation in breast cancer. Translation (Austin) (2014) 0.75
TLR2(-/-) Mice Display Decreased Severity of Giardiasis via Enhanced Proinflammatory Cytokines Production Dependent on AKT Signal Pathway. Front Immunol (2017) 0.75
Human bocavirus induces apoptosis and autophagy in human bronchial epithelial cells. Exp Ther Med (2017) 0.75
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol (2002) 17.41
Perturbations of the AKT signaling pathway in human cancer. Oncogene (2005) 6.64
MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther (2010) 5.24
Structure, regulation and function of PKB/AKT--a major therapeutic target. Biochim Biophys Acta (2004) 4.11
Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents. J Cell Biol (2008) 3.36
Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene (2008) 3.31
Phosphorylation of elongation factor 2 by EF-2 kinase affects rate of translation. Nature (1988) 2.71
Simultaneous induction of non-canonical autophagy and apoptosis in cancer cells by ROS-dependent ERK and JNK activation. PLoS One (2010) 2.45
Modulation of intracellular ROS levels by TIGAR controls autophagy. EMBO J (2009) 2.31
Elongation factor-2 kinase regulates autophagy in human glioblastoma cells. Cancer Res (2006) 1.89
Macroautophagy versus mitochondrial autophagy: a question of fate? Cell Death Differ (2005) 1.65
Putting the rap on Akt. J Clin Oncol (2004) 1.51
Akt inhibitor shows anticancer and radiosensitizing effects in malignant glioma cells by inducing autophagy. Int J Oncol (2007) 1.45
Allosteric inhibitors of Akt1 and Akt2: a naphthyridinone with efficacy in an A2780 tumor xenograft model. Bioorg Med Chem Lett (2008) 1.44
Silencing of elongation factor-2 kinase potentiates the effect of 2-deoxy-D-glucose against human glioma cells through blunting of autophagy. Cancer Res (2009) 1.42
Identification and characterization of an inhibitor of eukaryotic elongation factor 2 kinase against human cancer cell lines. Cancer Res (2003) 1.33
Ca2+/calmodulin-dependent phosphorylation of elongation factor 2. FEBS Lett (1987) 1.30
Cytoprotective effect of the elongation factor-2 kinase-mediated autophagy in breast cancer cells subjected to growth factor inhibition. PLoS One (2010) 1.29
Doctor Jekyll and Mister Hyde: autophagy can promote both cell survival and cell death. Cell Death Differ (2005) 1.28
Activity and regulation by growth factors of calmodulin-dependent protein kinase III (elongation factor 2-kinase) in human breast cancer. Br J Cancer (1999) 1.26
Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer. J Clin Oncol (2008) 1.17
Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT. Invest New Drugs (2010) 1.16
Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia. Clin Cancer Res (2010) 1.16
Phosphorylation of elongation factor 2 in normal and malignant rat glial cells. Cancer Res (1993) 1.05
Role of calmodulin-dependent phosphorylation of elongation factor 2 in the proliferation of rat glial cells. Cell Growth Differ (1994) 1.01
Calmodulin-dependent protein kinases in rat glioblastoma. Cell Growth Differ (1995) 0.94
Galaxy: a platform for interactive large-scale genome analysis. Genome Res (2005) 35.75
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet (2005) 29.45
Genome sequence of the Brown Norway rat yields insights into mammalian evolution. Nature (2004) 24.40
Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science (2002) 24.31
R/qtl: QTL mapping in experimental crosses. Bioinformatics (2003) 22.38
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature (2010) 18.63
Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science (2011) 14.29
Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell (2013) 13.37
The diverse functions of histone lysine methylation. Nat Rev Mol Cell Biol (2005) 12.70
Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell (2011) 11.44
Histone demethylation by a family of JmjC domain-containing proteins. Nature (2005) 10.36
Role of histone H3 lysine 27 methylation in X inactivation. Science (2003) 9.85
Role of histone H2A ubiquitination in Polycomb silencing. Nature (2004) 9.48
Active DNA demethylation: many roads lead to Rome. Nat Rev Mol Cell Biol (2010) 9.35
Increased methylation variation in epigenetic domains across cancer types. Nat Genet (2011) 8.92
DNA methylation-related chromatin remodeling in activity-dependent BDNF gene regulation. Science (2003) 8.81
Comprehensive high-throughput arrays for relative methylation (CHARM). Genome Res (2008) 8.62
Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res (2007) 8.41
The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Curr Opin Genet Dev (2004) 7.89
SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex. Mol Cell (2004) 6.90
The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science (2011) 6.75
Hydrogen-bonded ferroelectrics based on metal-organic coordination. J Am Chem Soc (2009) 6.69
JmjC-domain-containing proteins and histone demethylation. Nat Rev Genet (2006) 6.65
Dual functions of Tet1 in transcriptional regulation in mouse embryonic stem cells. Nature (2011) 6.48
Role of Bmi-1 and Ring1A in H2A ubiquitylation and Hox gene silencing. Mol Cell (2005) 6.29
Regulation of histone methylation by demethylimination and demethylation. Nat Rev Mol Cell Biol (2007) 6.13
A framework for collaborative analysis of ENCODE data: making large-scale analyses biologist-friendly. Genome Res (2007) 5.97
hDOT1L links histone methylation to leukemogenesis. Cell (2005) 5.83
Structural basis for specific binding of Polycomb chromodomain to histone H3 methylated at Lys 27. Genes Dev (2003) 5.77
JHDM2A, a JmjC-containing H3K9 demethylase, facilitates transcription activation by androgen receptor. Cell (2006) 5.54
Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain. Curr Biol (2002) 5.53
Large histone H3 lysine 9 dimethylated chromatin blocks distinguish differentiated from embryonic stem cells. Nat Genet (2009) 5.52
The transcriptional repressor JHDM3A demethylates trimethyl histone H3 lysine 9 and lysine 36. Nature (2006) 5.51
New nomenclature for chromatin-modifying enzymes. Cell (2007) 5.34
Tudor, MBT and chromo domains gauge the degree of lysine methylation. EMBO Rep (2006) 5.19
G9a-mediated irreversible epigenetic inactivation of Oct-3/4 during early embryogenesis. Nat Cell Biol (2006) 5.16
Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol (2004) 5.12
Unique physiological and pathogenic features of Leptospira interrogans revealed by whole-genome sequencing. Nature (2003) 5.04
ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science (2004) 4.81
Supramolecular bola-like ferroelectric: 4-methoxyanilinium tetrafluoroborate-18-crown-6. J Am Chem Soc (2011) 4.73
Genome-wide analysis of PTB-RNA interactions reveals a strategy used by the general splicing repressor to modulate exon inclusion or skipping. Mol Cell (2009) 4.71
Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling. Nature (2010) 4.61
Dnmt3a-dependent nonpromoter DNA methylation facilitates transcription of neurogenic genes. Science (2010) 4.60
Recognition of histone H3 lysine-4 methylation by the double tudor domain of JMJD2A. Science (2006) 4.54
First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol (2011) 4.53
Bre1, an E3 ubiquitin ligase required for recruitment and substrate selection of Rad6 at a promoter. Mol Cell (2003) 4.49
Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol (2008) 4.45
Genome-wide analysis of 5-hydroxymethylcytosine distribution reveals its dual function in transcriptional regulation in mouse embryonic stem cells. Genes Dev (2011) 4.45
Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis. JAMA (2007) 4.40
The zinc finger transcription factor Th-POK regulates CD4 versus CD8 T-cell lineage commitment. Nature (2005) 4.39
Sequence and analysis of rice chromosome 4. Nature (2002) 4.39
Subtypes of breast cancer show preferential site of relapse. Cancer Res (2008) 4.38
Diisopropylammonium chloride: a ferroelectric organic salt with a high phase transition temperature and practical utilization level of spontaneous polarization. Adv Mater (2011) 4.30
Nanog and Oct4 associate with unique transcriptional repression complexes in embryonic stem cells. Nat Cell Biol (2008) 4.30
The RIP1/RIP3 necrosome forms a functional amyloid signaling complex required for programmed necrosis. Cell (2012) 4.29
Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res (2003) 4.28
Targeted genome modification of crop plants using a CRISPR-Cas system. Nat Biotechnol (2013) 4.19
5-hmC-mediated epigenetic dynamics during postnatal neurodevelopment and aging. Nat Neurosci (2011) 4.15
Replication-dependent loss of 5-hydroxymethylcytosine in mouse preimplantation embryos. Science (2011) 4.12
Purification and functional characterization of SET8, a nucleosomal histone H4-lysine 20-specific methyltransferase. Curr Biol (2002) 4.12
Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res (2006) 4.11
Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood (2005) 4.10
Mechanisms and functions of Tet protein-mediated 5-methylcytosine oxidation. Genes Dev (2011) 4.09
Lysine methylation within the globular domain of histone H3 by Dot1 is important for telomeric silencing and Sir protein association. Genes Dev (2002) 4.07
Meta-analysis of genome-wide association studies identifies common variants associated with blood pressure variation in east Asians. Nat Genet (2011) 4.04
Lung metastasis genes couple breast tumor size and metastatic spread. Proc Natl Acad Sci U S A (2007) 3.92
Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: implications for Lewy body formation. J Neurosci (2005) 3.92
Distinct molecular mechanism for initiating TRAF6 signalling. Nature (2002) 3.82
The H3K36 demethylase Jhdm1b/Kdm2b regulates cell proliferation and senescence through p15(Ink4b). Nat Struct Mol Biol (2008) 3.80
Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res (2004) 3.80
The retinoblastoma binding protein RBP2 is an H3K4 demethylase. Cell (2007) 3.79
Hierarchical recruitment of polycomb group silencing complexes. Mol Cell (2004) 3.73
PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation. Mol Cell (2007) 3.68
Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry (2010) 3.64
The death domain superfamily in intracellular signaling of apoptosis and inflammation. Annu Rev Immunol (2007) 3.59
Site-specific Lys-63-linked tumor necrosis factor receptor-associated factor 6 auto-ubiquitination is a critical determinant of I kappa B kinase activation. J Biol Chem (2006) 3.51
TET enzymes, TDG and the dynamics of DNA demethylation. Nature (2013) 3.49
Histone H3 and H4 ubiquitylation by the CUL4-DDB-ROC1 ubiquitin ligase facilitates cellular response to DNA damage. Mol Cell (2006) 3.39
Imprinting along the Kcnq1 domain on mouse chromosome 7 involves repressive histone methylation and recruitment of Polycomb group complexes. Nat Genet (2004) 3.33
All TRAFs are not created equal: common and distinct molecular mechanisms of TRAF-mediated signal transduction. J Cell Sci (2002) 3.31
pRB family proteins are required for H3K27 trimethylation and Polycomb repression complexes binding to and silencing p16INK4alpha tumor suppressor gene. Genes Dev (2007) 3.31
A role for the elongator complex in zygotic paternal genome demethylation. Nature (2010) 3.27
Genes associated with breast cancer metastatic to bone. J Clin Oncol (2006) 3.21
Ubiquitination of histone H2B by Rad6 is required for efficient Dot1-mediated methylation of histone H3 lysine 79. J Biol Chem (2002) 3.14
5H-Dibenzo[c,h]1,6-naphthyridin-6-ones: novel topoisomerase I-targeting anticancer agents with potent cytotoxic activity. Bioorg Med Chem (2003) 3.13
Osteopontin expression correlates with melanoma invasion. J Invest Dermatol (2005) 3.13
Genome-wide profiling of 5-formylcytosine reveals its roles in epigenetic priming. Cell (2013) 3.13
Genome-wide analysis reveals TET- and TDG-dependent 5-methylcytosine oxidation dynamics. Cell (2013) 3.09
De novo rates and selection of large copy number variation. Genome Res (2010) 3.08
Sibling recurrence and the genetic epidemiology of autism. Am J Psychiatry (2010) 3.07
Effects of HER2 overexpression on cell signaling networks governing proliferation and migration. Mol Syst Biol (2006) 3.01
Genome-scale epigenetic reprogramming during epithelial-to-mesenchymal transition. Nat Struct Mol Biol (2011) 3.00
Histone modifications around individual BDNF gene promoters in prefrontal cortex are associated with extinction of conditioned fear. Learn Mem (2007) 2.99
Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res (2005) 2.98
Familial aggregation of quantitative autistic traits in multiplex versus simplex autism. Am J Med Genet B Neuropsychiatr Genet (2009) 2.98